Clinical trial
A Phase IIb, Randomized, Multi-Center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
NCT05357950 is registered in ClinicalTrials.gov with NeuroSense Therapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Randomized, Multi-Center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
- Lead sponsor
- NeuroSense Therapeutics Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2022
- Completion date
- November 4, 2024
- Enrollment
- 69 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.